198 results
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
Financial Statements; No Material Adverse Effect.
5.06 Litigation.
5.07 No Default.
5.08 Ownership of Property.
5.09 Environmental Matters.
5.10 … Covenant to Guarantee Obligations.
6.14 Covenant to Give Security.
ii
6.15 Compliance with Environmental Laws.
6.16 Anti-Corruption Laws; Sanctions
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
, income, gross receipts, employment, estimated, excise, severance, stamp, occupation, premium, windfall profits, environmental, custom duties, property
S-3ASR
EX-1.2
k56298dhopbe
30 Sep 22
Automatic shelf registration
4:17pm
425
nbw7cubhrtjglx4aptwj
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.1
yc19uxzkx3b5yg
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.2
gkbwoq dihb
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-99.1
2eqhc ohey
20 Oct 20
Results of Operations and Financial Condition
10:52am
8-K
EX-10.2
rx8ftd
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
8-K
EX-10.1
c5vonaj2l1aewpc
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
8-K
EX-10.4
dg7vit23t ql62t3sng
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
SC TO-T
EX-99
q3q juga1yp2zsgli9jt
31 Aug 20
Third party tender offer statement
8:46am
SC TO-C
EX-2.1
9wkh9zu 5ar
10 Aug 20
Information about tender offer
9:50pm